GSK/XenoPort Next-Generation RLS Drug Shows Efficacy In Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA filing for the non-dopaminergic candidate is on track for third quarter.
You may also be interested in...
FDA Wants Solzira Restless Legs Data Reformatted
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
FDA Wants Solzira Restless Legs Data Reformatted
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”
GSK, XenoPort Will Include Two-Dose Data In NDA For Restless Legs Drug
Positive efficacy with 600 mg a "surprise," XenoPort CEO says.